MOTS-C is the only peptide most people will ever inject that’s encoded inside their mitochondria. Most peptides are made by your DNA in the cell nucleus. MOTS-C is encoded in mitochondrial DNA — a 16-amino-acid peptide your mitochondria release as a signaling molecule to communicate with the rest of the body.
That mitochondrial origin is the whole story. MOTS-C exists to coordinate metabolism between organs, and synthetic MOTS-C lets you amplify that signal beyond what your aging mitochondria are producing on their own.
Mechanism, briefly
MOTS-C activates AMPK — the master energy-sensing enzyme that gets activated by exercise, fasting, and caloric restriction. AMPK activation drives:
- Improved insulin sensitivity in muscle
- Increased fatty acid oxidation (mitochondrial fat burning)
- Reduced hepatic glucose output
- Enhanced glucose uptake into peripheral tissues
In short: MOTS-C tells your body to behave like it’s been exercising and fasting, without the exercise or fasting. A direct comparison study in animal models showed that MOTS-C at 0.5 mg/kg daily for 8 weeks produced comparable PGC-1α expression, GLUT4 expression, and intracellular MOTS-C levels to treadmill exercise — confirming its classification as an exercise mimetic.
It does some of what metformin does, but through a different upstream mechanism: mitochondrial signaling rather than complex I inhibition.
What it actually does in users
The real-world effects users report:
- Improved exercise tolerance — the same workout feels easier at the same heart rate
- Faster recovery between training sessions
- Stable energy through the day — fewer crashes after meals
- Better glucose response in users who track CGM data (lower spikes, faster return to baseline)
- Mild fat loss in some users, especially when combined with caloric restriction
Effects scale with baseline. Metabolically healthy people feel modest changes. People with insulin resistance or pre-diabetes report more dramatic effects — MOTS-C is one of the few peptides where the response is clearly tied to baseline metabolic dysfunction.
Dosing protocols
A 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL working solution. Dose ranges based on field use and self-experimentation reports:
- Low/standard: 0.5–1 mg SubQ, 3–5 times per week on workout days, or daily. This is the consensus starting point. Energy effect typically lasts 24–48 hours at this range, so daily dosing is not required. Injection-site reactions are mild at this dose: slight redness and itch that resolves within 24 hours.
- Higher: 2.5–5 mg SubQ or IM, 1–2 times per week. At 2.5–5 mg SubQ, expect a credit-card-sized cellulitis-like red patch at the injection site that typically resolves within 1–2 hours. At 2.5–5 mg IM using a 13 mm or 1-inch needle (deep muscle), the skin rash largely disappears but the energy wave post-injection is more intense and can last over 30 minutes, followed by sustained elevation for several days.
Important:Beyond 5 mg per injection is the danger zone regardless of route. Injection-site reactions become severe, and anaphylactic shock has been reported — including cases where a vein was struck during IM injection. Have an EpiPen available if experimenting above 2.5 mg. Diluting MOTS-C to a lower concentration does not reliably prevent these reactions.
The 0.5–1 mg SubQ protocol is what most experienced users settle on. The energy duration is long enough that higher, less-frequent doses offer little practical advantage while substantially raising adverse reaction risk. The 2.5–5 mg IM range is used by some for twice-weekly dosing convenience, but it requires IM technique and the energy wave can be overwhelming for some users.
For per-shot math on your specific vial, use the MOTS-C reconstitution calculator and enter the numbers manually.
Stacking
MOTS-C stacks naturally with metabolic and longevity-side compounds:
- MOTS-C + Tirzepatide or Retatrutide — different mechanisms. The GLP-1 family is appetite-side; MOTS-C is energy-side. The combination delivers more body composition change than either alone.
- MOTS-C + NAD+ — both mitochondria-focused. NAD+ provides substrate, MOTS-C provides signal. Common longevity stack.
- MOTS-C + 5-Amino-1MQ — both NNMT/AMPK-axis. The pair is heavy on metabolic remodeling.
MOTS-C does not stack meaningfully with healing peptides (BPC-157, TB-500, KLOW) — different mechanisms, no overlap, no interaction concerns either way.
The honest caveats
- MOTS-C has no human clinical trial data. All benefit evidence comes from animal models and accumulating self-experimentation reports. The mechanism is well-characterized; long-term human safety is not established. The FDA cited the lack of human exposure data when restricting compounding pharmacy access in September 2023.
- Effects are subtle at the start. Most users need 3–4 weeks of consistent dosing to feel changes. If you’re looking for a peptide that hits hard in week one, MOTS-C isn’t it.
- Injection-site reactions are the primary practical concern. Start at 0.5 mg and build up. Reactions get progressively worse with dose; beyond 5 mg per injection, severe reactions including anaphylaxis become a real risk.
- Diabetic users should monitor blood glucose carefully — MOTS-C can produce mild hypoglycemia in users already on glucose-lowering medication.
- WADA added MOTS-C to its 2025 prohibited list. Not for tested athletes.
Where to buy
NovaPeptide sells MOTS-C in 10 mg vials with third-party COA on every batch. Use the BIOHACKMAXX code at checkout.
Bottom line
MOTS-C is the peptide for people who want metabolic benefits without the appetite suppression of the GLP-1 family. It’s not a fat-loss tool primarily — it’s a metabolic remodeling tool. Start low (0.5–1 mg), stay SubQ until you understand your individual response, and combine it with other mitochondrial support compounds to get synergistic effects without needing to push the dose into adverse-reaction territory.
For the full reconstitution math, the MOTS-C calculator handles any vial size. For the bigger metabolic stack, the Peptide Guidecovers MOTS-C’s role alongside the GLP-1 family and longevity peptides.